French officials force Takeda to pull Actos off market

Takeda has officially taken its diabetes drug Actos off the market in France at the request of the country's medicines regulator, which is concerned about a potential link with bladder cancer. A safety review by the European Medicines Agency is ongoing. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.